FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2021/11/038131 [Registered on: 18/11/2021] Trial Registered Prospectively
Last Modified On: 11/01/2022
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Cohort Study 
Study Design  Single Arm Study 
Public Title of Study   Development of artificial intelligence based model to predict mortality in patients with acute-on-chronic liver failure 
Scientific Title of Study   Development, validation and deployment of a novel prediction model utilizing artificial intelligence on clinical and proteomic features to predict mortality among patients with acute-on-chronic liver failure 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Nipun Verma 
Designation  Assistant Professor 
Affiliation  PGIMER, Chandigarh 
Address  Department of Hepatology, Nehru Hospital Extension Block, PGIMER, Sector-12

Chandigarh
CHANDIGARH
160012
India 
Phone  9914208562  
Fax    
Email  nipun29j@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Nipun Verma 
Designation  Assistant Professor 
Affiliation  PGIMER, Chandigarh 
Address  Department of Hepatology, Nehru Hospital Extension Block, PGIMER, Sector-12


CHANDIGARH
160012
India 
Phone  9914208562  
Fax    
Email  nipun29j@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Nipun Verma 
Designation  Assistant Professor 
Affiliation  PGIMER, Chandigarh 
Address  Department of Hepatology, Nehru Hospital Extension Block, PGIMER, Sector-12


CHANDIGARH
160012
India 
Phone  9914208562  
Fax    
Email  nipun29j@gmail.com  
 
Source of Monetary or Material Support  
IHUB Anubhuti IITD Foundation (TIH), New Delhi, India  
 
Primary Sponsor  
Name  IHUB Anubhuti IITD Foundation TIH 
Address  Indraprastha Institute of Information Technology Delhi, Okhla Industrial Estate, Phase-III, New Delhi-110020 
Type of Sponsor  Other [Non-Profit Company] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Nipun Verma  Post Graduate Institute of Medical Education and Research, Chandigarh  Department of Hepatology, Nehru Hospital Extension Block, PGIMER, Sector-12
Chandigarh
CHANDIGARH 
9914208562

nipun29j@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institute Ethics committee, PGIMER  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K74||Fibrosis and cirrhosis of liver,  
 
Intervention / Comparator Agent  
Type  Name  Details 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  Patients with a confirmed diagnosis of ACLF either by EASL criteria or by APASL criteria 
 
ExclusionCriteria 
Details  Patients with HIV infection, pregnant or lactating women, patients having any active malignancy or previous organ-transplantation and those refusing to give a consent will be excluded 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Derivation of AI/ML model for prediction of mortality in ACLF patients  After establishment of clinical and proteomic database, model derivation phase will began in first one and a half year 
 
Secondary Outcome  
Outcome  TimePoints 
Development of web application for AI model deployment  After internal validation of model, a validation cohort will be recruited and for model validation and refinement in next one and a half year 
 
Target Sample Size   Total Sample Size="200"
Sample Size from India="200" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   24/11/2021 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="3"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Open to Recruitment 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details    
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Liver cirrhosis is the most common cause of death among gastrointestinal diseases, with a global burden of 1.5 billion persons being affected annually. It is the 4th and 10th most common cause of disease in males and females, respectively. Acute-on-chronic liver failure (ACLF) development is the most common cause of death in these patients. The mortality of this dynamic syndrome ranges from 15-100% within 30-days and 90-100% within one year of presentation. Multiple life-threatening events like sepsis, organ failures, and gastrointestinal bleeding may occur during its course. This proposal is aimed to develop, validate, and deploy a novel model to predict mortality among patients with acute-on-chronic liver failure (ACLF). The model will be derived from clinical, biochemical, radiological and plasma proteomics data obtained from patients with ACLF. Principles of AI, machine learning, and bioinformatics will be utilized to build such a model. The model aims to incorporate the systems approach to medicine with clinical sciences and information technology sector. The proposal includes multiple innovations. It will develop a multimedia processing engine (converting the existing data in a ready format for ML and AI modeling), development, and deployment of AI-derived model for real-time predictive analytics. The models’ deployment will contribute to the development of user-friendly data analytic apps. The models may be used to assess the futility of care and allocate significant resources like ICU and mechanical ventilators to deserving patients. Importantly, patients’ lives can be saved with a timely decision for definitive treatment (liver transplant) using these models.

This proposal aligns with the mandate of TiH in terms of knowledge generation (development of clinical and proteomic database), technology product development (portable AI model), skill development (integration of skills such as clinical, biochemical, bioinformatics and information technology), collaboration (between clinicians, basic scientist, computational biologist, and information technologist). 
Close